Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology <scp>W</scp> orking <scp>G</scp> roup on <scp>M</scp> yocardial and <scp>P</scp> ericardial <scp>D</scp> iseases

Pablo García‐Pavía(Universidad Francisco de Vitoria), Aleš Linhart(Charles University), Claudio Rapezzi(University of Ferrara), Urs Eriksson(GZO Spital Wetzikon), Ingrid Kindermann(Baker Heart and Diabetes Institute), Michael Arad(Tel Aviv University), Sabine Pankuweit(Universitätsklinikum Gießen und Marburg), Marianna Fontana(Amyloidosis Foundation), Massimo Imazio(University of Udine), Alida L.P. Caforio(University of Padua), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Matthew J. Maurer(Mayo Clinic in Arizona), Stéphane Heymans(Maastricht University Medical Centre), Yehuda Adler, Arnt V. Kristen(Heidelberg University), Thibaud Damy(Amyloidosis Foundation), Martha Grogan(Mayo Clinic in Arizona), Cristina Basso(University of Padua), Esther González-López(Centro de Investigación en Red en Enfermedades Cardiovasculares), Giampaolo Merlini(University of Pavia), Ivana Burazor(University of Belgrade), Angelos G. Rigopoulos(Luther University), Antonis Pantazis(Harefield Hospital), Antonio Brucato(Azienda Ospedaliera Fatebenefratelli e Oftalmico)
European Journal of Heart Failure
April 1, 2021
Cited by 330


Related Papers